Published in Am J Prev Med on January 01, 2013
Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med (2014) 2.08
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One (2014) 1.35
Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc (2014) 1.34
Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco. AIDS Patient Care STDS (2013) 1.14
Antiretroviral pharmacology in mucosal tissues. J Acquir Immune Defic Syndr (2013) 1.07
Vulnerable infected populations and street markets for ARVs: Potential implications for PrEP rollout in the USA. AIDS Care (2013) 1.05
Advances in HIV prevention for serodiscordant couples. Curr HIV/AIDS Rep (2014) 1.02
Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. AIDS Patient Care STDS (2014) 1.02
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr (2014) 1.00
Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial. AIDS Behav (2015) 0.98
Perceptions of and intentions to adopt HIV pre-exposure prophylaxis among black men who have sex with men in Los Angeles. Int J STD AIDS (2015) 0.92
Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions. HIV Med (2014) 0.91
The current status of the use of oral medication to prevent HIV transmission. Curr Opin HIV AIDS (2015) 0.88
Incorporating couples-based approaches into HIV prevention for gay and bisexual men: opportunities and challenges. Arch Sex Behav (2014) 0.85
Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions. AIDS Behav (2016) 0.85
Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010. AIDS Behav (2015) 0.84
Preferences for daily or intermittent pre-exposure prophylaxis regimens and ability to anticipate sex among HIV uninfected members of Kenyan HIV serodiscordant couples. AIDS Behav (2014) 0.84
Knowledge, Attitudes, and Experiences of HIV Pre-Exposure Prophylaxis (PrEP) Trial Participants in Botswana. World J AIDS (2015) 0.79
Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study. J Acquir Immune Defic Syndr (2016) 0.78
Preexposure Prophylaxis Modality Preferences Among Men Who Have Sex With Men and Use Social Media in the United States. J Med Internet Res (2016) 0.77
Safety and tolerability of tenofovir for preexposure prophylaxis among men who have sex with men. J Acquir Immune Defic Syndr (2013) 0.75
Sharing of Investigational Drug Among Participants in the Voice Trial. AIDS Behav (2016) 0.75
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. J Virus Erad (2017) 0.75
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health (2004) 10.12
A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (2002) 3.41
The efficacy of behavioral interventions in reducing HIV risk behaviors and incident sexually transmitted diseases in heterosexual African Americans. AIDS (2008) 2.65
Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol (2011) 2.65
Prevalence of and risk factors for viral infections among human immunodeficiency virus (HIV)-infected and high-risk HIV-uninfected women. J Infect Dis (2003) 1.27
Talking about sex in Botswana: social desirability bias and possible implications for HIV-prevention research. Afr J AIDS Res (2006) 1.03
Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV. Am J Prev Med (2013) 1.00
Use of highly active antiretroviral therapy in HIV-infected women: impact of HIV specialist care. J Acquir Immune Defic Syndr (2002) 1.00
Race and the Public Health Impact Potential of Pre-Exposure Prophylaxis in the United States. J Acquir Immune Defic Syndr (2015) 0.96
Designing for diffusion of a biomedical intervention. Am J Prev Med (2013) 0.96
Knowledge of and interest in using preexposure prophylaxis for HIV prevention among men who have sex with men in Thailand. J Int Assoc Provid AIDS Care (2013) 0.93
Evaluation of possible effects of continued drug use on HIV progression among women. Int J STD AIDS (2004) 0.89
Introducing wicked issues for HIV pre-exposure prophylaxis implementation in the U.S. Am J Prev Med (2013) 0.86
Incorporating couples-based approaches into HIV prevention for gay and bisexual men: opportunities and challenges. Arch Sex Behav (2014) 0.85
Perceptions of door-to-door HIV counselling and testing in Botswana. SAHARA J (2011) 0.78
Process maps in clinical trial quality assurance. Clin Trials (2009) 0.78
Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition--United States, 2015. J Miss State Med Assoc (2015) 0.78
Urinary tract infections in women with or at risk for human immunodeficiency virus infection. Am J Obstet Gynecol (2002) 0.77
Strategies for Preventing HIV Infection Among HIV-Uninfected Women Attempting Conception with HIV-Infected Men - United States. MMWR Morb Mortal Wkly Rep (2017) 0.76
Levels of intracellular phosphorylated tenofovir and emtricitabine correlate with natural substrate concentrations in peripheral blood mononuclear cells of persons prescribed daily oral TruvadaTM for HIV pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2017) 0.75
Effects of Antiretroviral Therapy to Prevent HIV Transmission to Women in Couples Attempting Conception When the Man Has HIV Infection - United States, 2017. MMWR Morb Mortal Wkly Rep (2017) 0.75
Human Immunodeficiency Virus Prevention With Preexposure Prophylaxis in Sexually Transmitted Disease Clinics. Sex Transm Dis (2016) 0.75